Gene · 580
Papers4,139
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
881 to 900 of 4,139
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Landscape of germline cancer predisposition mutations testing and management in pediatrics: Implications for research and clinical care. | Front Pediatr | 2022 | 36225340 | PubTator, text mining | PubMed |
| Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland. | Prostate Int | 2022 | 36225282 | PubTator, text mining | PubMed |
| Pan-cancer analysis of LncRNA XIST and its potential mechanisms in human cancers. | Heliyon | 2022 | 36212008 | PubTator, text mining | PubMed |
| Ex vivo exposures to arsenite and its methylated trivalent metabolites alter gene transcription in mouse sperm cells. | Toxicol Appl Pharmacol | 2022 | 36209798 | PubTator, text mining | PubMed |
| The prevalence and prognosis of next-generation therapeutic targets in metastatic castration-resistant prostate cancer. | Mol Oncol | 2022 | 36209367 | PubTator, text mining | PubMed |
| Segregation analysis of 17,425 population-based breast cancer families: Evidence for genetic susceptibility and risk prediction. | Am J Hum Genet | 2022 | 36206742 | PubTator, text mining | PubMed |
| Spectrum and management of breast cancer patients with variant of uncertain significance mutations at a tertiary care centre in North India. | Ecancermedicalscience | 2022 | 36200007 | PubTator, text mining | PubMed |
Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations. | Ther Adv Med Oncol | 2022 | 36199621 | PubTator, text mining | PubMed |
| BRCA1-associated RING domain-1 (BARD1) loss and GBP1 expression enhance sensitivity to DNA damage in Ewing sarcoma. | Cancer Res Commun | 2022 | 36187937 | PubTator, text mining | PubMed |
| Regulation of Pdx1 by oxidative stress and Nrf2 in pancreatic beta-cells. | Front Endocrinol (Lausanne) | 2022 | 36187092 | PubTator, text mining | PubMed |
| Single-molecule fluorescence imaging techniques reveal molecular mechanisms underlying deoxyribonucleic acid damage repair. | Front Bioeng Biotechnol | 2022 | 36185427 | PubTator, text mining | PubMed |
| Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: A case report. | Medicine (Baltimore) | 2022 | 36181052 | PubTator, text mining | PubMed |
| Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of "Second Hit" in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma. | Mol Diagn Ther | 2022 | 36178671 | PubTator, text mining | PubMed |
| Association between fertility treatments and breast cancer risk in women with a family history or BRCA mutations: a systematic review and meta-analysis. | Front Endocrinol (Lausanne) | 2022 | 36176466 | PubTator, text mining | PubMed |
| Pro-metastatic and mesenchymal gene expression signatures characterize circulating tumor cells of neuroblastoma patients with bone marrow metastases and relapse. | Front Oncol | 2022 | 36176417 | PubTator, text mining | PubMed |
| Downregulation of circLIFR exerts cancer-promoting effects on hepatocellular carcinoma in vitro. | Front Genet | 2022 | 36176304 | PubTator, text mining | PubMed |
| Germline RB1 Mutation in Retinoblastoma Patients: Detection Methods and Implication in Tumor Focality. | Transl Vis Sci Technol | 2022 | 36173648 | PubTator, text mining | PubMed |
| Regulation and roles of FOXK2 in cancer. | Front Oncol | 2022 | 36172141 | PubTator, text mining | PubMed |
Detection of BRCA1/2 pathogenic variants in patients with breast and/or ovarian cancer and their families. Analysis of 3,458 cases from Lower Silesia (Poland) according to the diagnostic algorithm of the National Cancer Control Programme. | Front Genet | 2022 | 36171877 | PubTator, text mining | PubMed |
| Applications for open access normalized synthesis in metastatic prostate cancer trials. | Front Artif Intell | 2022 | 36171797 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/580/papers?page=45